CB1 cannabinoid receptors mediate endochondral skeletal growth attenuation by Δ9‐tetrahydrocannabinol. (January 2015)

• Record Type: Journal Article
• Authors: Wasserman, Elad; Tam, Joseph; Mechoulam, Raphael; Zimmer, Andreas; Maor, Gila; Bab, Itai
• Other Names: Zaidi Mone guestEditor.
• Is Part Of: Annals of the New York Academy of Sciences. Volume 1335(2015)
• Page Start: 110
• Page End: 119
• Publication Date: 2015-01
• Subjects: cannabinoids -- cannabinoid receptors -- diacylglicerol lipases -- epiphyseal growth cartilage -- hypertrophic chondrocytes -- tetrahydrocannabinol; Medical sciences -- Periodicals; Medicine -- Periodicals; Science -- Periodicals; 610
• DOI: 10.1111/nyas.12642
• Languages: English
• ISSNs: 0077-8923

Abstract

Abstract : The endocannabinoid (EC) system regulates bone mass. Because cannabis use during pregnancy results in stature shorter than normal, we examined the role of the EC system in skeletal elongation. We show that CB1 and CB2 cannabinoid receptors are expressed specifically in hypertrophic chondrocytes of the epiphyseal growth cartilage (EGC), which drives vertebrate growth. These cells also express diacylglycerol lipases, critical biosynthetic enzymes of the main EC, and 2‐arachidonoylglycerol (2‐AG), which is present at significant levels in the EGC. Femora of CB1‐ and/or CB2‐deficient mice at the end of the rapid growth phase are longer compared to wild‐type (WT) animals. We find that Δ 9 ‐tetrahydrocannabinol (THC) slows skeletal elongation of female WT and CB2‐, but not CB1‐, deficient mice, which is reflected in femoral and lumbar vertebral body length. This in turn results in lower body weight, but unaltered fat content. THC inhibits EGC chondrocyte hypertrophy in ex vivo cultures and reduces the hypertrophic cell zone thickness of CB1‐, but not CB2‐, deficient mice. These results demonstrate a local growth‐restraining EC system in the EGC. The relevance of the present findings to humans remains to be studied.